1,2,3-trichloropropane: Carcinogenic Potency Database

1,2,3-Trichloropropane (CAS 96-18-4)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
ezy kid orc pan pre sto	cli ezy mgl orc sto	hag liv sto	hag liv orc sto ute	1.35^m	0.875^m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: cli = clitoral gland. ezy = ear/Zymbal’s gland. hag = harderian gland. kid = kidney. liv = liver. mgl = mammary gland. orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). pan = pancreas. pre = preputial gland. sto = stomach. ute = uterus. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

1,2,3-Trichloropropane: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

1,2,3-TRICHLOROPROPANE   96-18-4
6297 M f b6c gav 20m24 TR384 :                       0    4.26mg  14.3mg  42.9mg
 MXB MXB a      .826mg Z P<.0005    .547mg 1.29mg   9/50   48/50   50/51   54/55   for:sqc,sqp; hag:ade,anb; liv:hpa,hpc; pal:sqc;
                                                                                                         phr:sqc; ute:ead,edc,esp. C
 for MXA a      .828mg * P<.0005 c  .551mg 1.26mg   0/50   48/50   50/51   54/55                                      for:sqc,sqp.
 for sqc a      .970mg * P<.0005 c  .649mg 1.46mg   0/50   46/50   49/51   49/55
 for sqp a      1.64mg * P<.0005 c  .972mg 2.90mg   0/50   23/50   18/51   29/55
 liv MXA a      2.93mg Z P<.0005 c  1.60mg 5.95mg   7/50   11/50    8/51   31/55                                      liv:hpa,hpc.
 liv hpa a      3.33mg Z P<.0005 c  1.77mg 6.82mg   6/50    9/50    8/51   31/55
 ute MXA a      6.62mg Z P<.0005 c  2.81mg 18.0mg   0/50    5/50    3/51    9/55                                      ute:ead,edc.
 hag MXA a      7.05mg Z P<.0005 c  3.10mg 18.1mg   2/50    6/50    7/51   10/55                                      hag:ade,anb.
 --- MXA a      7.08mg * P<.002     2.54mg 63.7mg  15/50    6/50    3/51    3/55                              ---:mlh,mlm,mlp,mlu. S
 ute edc a      8.47mg Z P<.0005 c  3.36mg 25.0mg   0/50    4/50    3/51    6/55
 --- MXA a      8.64mg * P<.006     2.80mg 193.mg  17/50    7/50    3/51    3/55                          ---:hcs,mlh,mlm,mlp,mlu. S
 lun MXA a      14.3mg Z P<.0005    4.56mg 68.9mg   7/50    3/50    0/51   10/55                                      lun:a/a,a/c. S
 lun a/a a      14.6mg Z P<.0005    4.46mg 71.5mg   4/50    3/50    0/51   10/55                                                   S
 ute esp a      22.9mg * P<.0005 c  5.82mg 148.mg   0/50    2/50    1/51    6/55
 liv hpc a      28.7mg * P<.01      6.25mg 6.07gm   1/50    3/50    0/51    2/55                                                   S
 ute ead a      34.9mg * P<.002  c  6.33mg 522.mg   0/50    1/50    0/51    3/55
 MXA MXA a      47.0mg * P<.0005    8.63mg 323.mg   1/50    0/50    2/51    5/55                    pal:sqc,sqp; phr:sqc; ton:sqp. S
 MXA sqc a      154.mg * P<.0005 c  50.7mg 600.mg   0/50    0/50    1/51    5/55                                 pal:sqc; phr:sqc.
 TBA MXB a      .806mg Z P<.0005    .537mg 1.27mg  36/50   48/50   50/51   55/55
 liv MXB a      2.93mg Z P<.0005    1.60mg 5.95mg   7/50   11/50    8/51   31/55                                  liv:hpa,hpb,hpc.
 lun MXB a      14.3mg Z P<.0005    4.56mg 68.9mg   7/50    3/50    0/51   10/55                                      lun:a/a,a/c.
6298 M m b6c gav 21m24 TR384 :                       0    4.24mg  14.3mg  42.8mg
 for MXA a      .928mg * P<.0005 c  .626mg 1.39mg   3/52   50/52   53/54   55/56                                      for:sqc,sqp.
 MXB MXB a      .996mg * P<.0005    .686mg 1.55mg  15/52   50/52   53/54   55/56                for:sqc,sqp; hag:ade; liv:hpa,hpc. C
 for sqc a      1.34mg * P<.0005 c  .910mg 1.98mg   0/52   40/52   50/54   51/56
 for sqp a      1.63mg * P<.0005 c  1.01mg 2.71mg   3/52   28/52   22/54   33/56
 liv MXA a      2.13mg Z P<.0005 c  1.31mg 3.64mg  13/52   24/52   24/54   31/56                                      liv:hpa,hpc.
 liv hpa a      2.87mg Z P<.0005 c  1.67mg 5.26mg  11/52   18/52   21/54   29/56
 liv hpc a      6.28mg * P<.0005    2.93mg 19.9mg   4/52   11/52    5/54    3/56                                                   S
 lun MXA a      9.32mg * P<.0005    3.57mg 49.7mg   8/52   11/52    5/54    6/56                                      lun:a/a,a/c. S
 lun a/a a      11.2mg * P<.0005    3.85mg 87.3mg   7/52   11/52    3/54    6/56                                                   S
 hag ade a      13.7mg Z P<.0005 c  6.13mg 30.8mg   1/52    2/52   10/54   11/56
 ton sqp a      454.mg * P<.02   e  103.mg n.s.s.   0/52    0/52    0/54    2/56
 TBA MXB a      1.06mg * P<.0005    .703mg 1.67mg  29/52   50/52   54/54   56/56
 liv MXB a      2.13mg Z P<.0005    1.31mg 3.64mg  13/52   24/52   24/54   31/56                                  liv:hpa,hpb,hpc.
 lun MXB a      9.32mg * P<.0005    3.57mg 49.7mg   8/52   11/52    5/54    6/56                                      lun:a/a,a/c.
6299 R f f34 gav 21m24 TR384 :                       0    2.12mg  7.05mg  21.4mg
 MXB MXB a      1.07mg Z P<.0005    .759mg 1.58mg  23/50   38/49   49/52   47/52    cli:ade,anb,car,cnb; for:sqc,sqp; mgl:adc,ade,
                                                                                      fba; pal:sqp; phr:sqc; ton:sqc,sqp; zym:car. C
 for MXA a      1.64mg Z P<.0005 c  1.14mg 2.43mg   0/50   16/49   37/52   19/52                                      for:sqc,sqp.
 for sqp a      1.94mg Z P<.0005 c  1.31mg 2.97mg   0/50   13/49   32/52   17/52
 mgl MXA a      1.98mg Z P<.0005 c  1.26mg 3.43mg  17/50   26/49   29/52   22/52                                  mgl:adc,ade,fba.
 MXA MXA a      2.93mg Z P<.0005 c  1.94mg 4.48mg   1/50    6/49   28/52   32/52                    pal:sqp; phr:sqc; ton:sqc,sqp.
 mgl MXA a      3.32mg * P<.0005    1.77mg 10.2mg  16/50   23/49   22/52    1/52                                      mgl:ade,fba. S
 mgl fba a      3.42mg * P<.0005    1.79mg 11.3mg  15/50   23/49   20/52    1/52                                                   S
 cli MXA a      3.58mg Z P<.0005 c  2.12mg 6.90mg   5/50   10/49   17/52   15/52                              cli:ade,anb,car,cnb.
 cli MXA a      4.04mg Z P<.0005 c  2.30mg 8.76mg   5/50   10/49   13/52   10/52                                      cli:ade,anb.
 ton MXA a      4.70mg Z P<.0005    2.84mg 7.94mg   0/50    3/49   18/52   23/52                                      ton:sqc,sqp. S
 MXA sqc a      5.12mg Z P<.0005 c  3.17mg 8.36mg   0/50    1/49   21/52   21/52                                 phr:sqc; ton:sqc.
 mgl MXA a      5.50mg Z P<.0005 c  3.21mg 10.0mg   2/50    6/49   14/52   21/52                                      mgl:adc,ade.
 mgl adc a      5.91mg Z P<.0005 c  3.38mg 10.9mg   1/50    6/49   12/52   21/52
 MXA sqp a      5.98mg Z P<.0005 c  3.36mg 11.4mg   1/50    5/49   10/52   18/52                                 pal:sqp; ton:sqp.
 for sqc a      7.77mg * P<.0005 c  4.00mg 17.1mg   0/50    3/49    9/52    4/52
 MXA sqc a      8.87mg Z P<.0005    4.89mg 16.3mg   0/50    1/49   10/52   15/52                                 pal:sqc; phr:sqc. S
 ton sqp a      9.61mg Z P<.0005    4.88mg 19.3mg   0/50    3/49    5/52   16/52                                                   S
 ton sqc a      10.1mg Z P<.0005    5.10mg 20.3mg   0/50    0/49   13/52    7/52                                                   S
 pal sqp a      18.5mg * P<.002     7.05mg 106.mg   1/50    2/49    5/52    2/52                                                   S
 thy MXA a      25.2mg * P<.0005    8.60mg 127.mg   0/50    1/49    3/52    2/52                                      thy:fca,fcc. S
 thy fca a      36.9mg * P<.0005    11.2mg 196.mg   0/50    0/49    3/52    2/52                                                   S
 cli MXA a      49.5mg * P<.0005 c  22.5mg 131.mg   0/50    0/49    4/52    6/52                                      cli:car,cnb.
 zym car a      59.0mg Z P<.003  c  15.8mg 579.mg   0/50    1/49    0/52    3/52
 MXA adc a      78.4mg * P<.004  e  18.6mg 925.mg   0/50    0/49    1/52    2/52                                 col:adc; jej:adc.
 --- mnl a      7.11mg * P<.02      2.96mg n.s.s.  13/50   17/49   14/52    0/52                                                   S
 TBA MXB a      1.02mg Z P<.0005    .710mg 1.54mg  48/50   46/49   51/52   48/52
 liv MXB a      81.4mg * P<.1       13.3mg n.s.s.   0/50    0/49    1/52    0/52                                  liv:hpa,hpb,hpc.
6300 R m f34 gav 22m24 TR384 :                       0    2.11mg  7.06mg  21.4mg
 MXB MXB a      1.10mg Z P<.0005    .803mg 1.57mg   8/50   41/50   45/49   51/52   for:sqc,sqp; kid:rua; pal:sqc,sqp; pan:ade,ana,
                                                                                           aoc; pre:ade,car; ton:sqc,sqp; zym:car. C
 for MXA a      1.15mg Z P<.0005 c  .860mg 1.58mg   0/50   33/50   42/49   43/52                                      for:sqc,sqp.
 tes MXA a      1.35mg Z P<.0005    .928mg 2.14mg  47/50   48/50   45/49   44/52                                      tes:iab,ica. S
 for sqp a      1.53mg Z P<.0005 c  1.12mg 2.13mg   0/50   29/50   33/49   38/52
 pan MXA a      1.65mg Z P<.0005 c  1.17mg 2.47mg   5/50   21/50   36/49   29/52                                  pan:ade,ana,aoc.
 pan MXA a      1.65mg Z P<.0005 c  1.17mg 2.47mg   5/50   21/50   36/49   29/52                                      pan:ade,ana.
 for sqc a      3.00mg Z P<.0005 c  2.00mg 4.70mg   0/50    9/50   27/49   13/52
 kid rua a      4.44mg Z P<.0005 c  2.83mg 7.28mg   0/50    2/50   20/49   21/52
 MXA MXA a      4.48mg Z P<.0005 c  2.96mg 6.96mg   1/50    4/50   18/49   40/52                         pal:sqc,sqp; ton:sqc,sqp.
 ton MXA a      7.86mg Z P<.0005    4.84mg 12.7mg   0/50    2/50    8/49   37/52                                      ton:sqc,sqp. S
 thy MXA a      8.15mg Z P<.0005    3.89mg 36.7mg   4/50   16/50    6/49    5/52                                      thy:cca,ccr. S
 MXA sqp a      8.16mg Z P<.0005 c  4.75mg 14.7mg   0/50    4/50    9/49   19/52                                 pal:sqp; ton:sqp.
 MXA sqc a      8.65mg Z P<.0005 c  4.98mg 15.7mg   1/50    0/50   11/49   25/52                                 pal:sqc; ton:sqc.
 pre MXA a      9.59mg Z P<.0005 c  5.16mg 21.5mg   5/50    6/50    8/49   16/52                                      pre:ade,car.
 ton sqp a      10.2mg Z P<.0005    5.67mg 19.1mg   0/50    2/50    8/49   18/52                                                   S
 thy cca a      10.3mg Z P<.002     4.49mg 66.6mg   4/50   15/50    4/49    5/52                                                   S
 pal sqc a      11.7mg Z P<.0005    5.94mg 27.6mg   1/50    0/50   11/49    7/52                                                   S
 --- mnl a      11.9mg Z P<.005     4.98mg 144.mg  16/50   11/50    9/49    6/52                                                   S
 pre ade a      14.0mg Z P<.0005 c  6.69mg 39.0mg   5/50    3/50    5/49   11/52
 sub MXA a      19.6mg * P<.008     7.64mg 665.mg   3/50    3/50    7/49    1/52                                      sub:fib,sar. S
 sub fib a      20.2mg * P<.006     7.87mg 295.mg   2/50    2/50    6/49    1/52                                                   S
 ski MXA a      20.8mg Z P<.0005    8.39mg 99.7mg   3/50    3/50    3/49    6/52                          ski:bcc,ker,sqc,sqp,tri. S
 liv MXA a      23.0mg * P<.0005    9.02mg 116.mg   1/50    1/50    4/49    3/52                                      liv:hpa,hpc. S
 pre car a      28.0mg * P<.0005 c  11.5mg 127.mg   0/50    3/50    3/49    5/52
 ton sqc a      34.7mg Z P<.0005    19.6mg 67.0mg   0/50    0/50    0/49   19/52                                                   S
 thy MXA a      35.2mg * P<.008     11.7mg 1.25gm   1/50    1/50    3/49    2/52                                      thy:fca,fcc. S
 pal sqp a      36.6mg * P<.002     12.7mg 309.mg   0/50    2/50    1/49    3/52                                                   S
 ski MXA a      39.6mg * P<.002     14.2mg 283.mg   0/50    2/50    1/49    3/52                                      ski:sqc,sqp. S
 pan aoc a      51.5mg * P<.005     14.2mg 771.mg   0/50    0/50    2/49    1/52                                                   S
 MXA MXA a      73.4mg * P<.0005 e  25.5mg 357.mg   0/50    0/50    2/49    3/52                    col:adc,adp; jej:adc; rec:adp.
 amd MXA a      11.4mg * P<.03      4.64mg n.s.s.  11/50    8/50   14/49    0/52                              amd:pbb,phc,phm,pob. S
 amd MXA a      12.4mg * P<.03      5.00mg n.s.s.  10/50    7/50   13/49    0/52                                      amd:pbb,pob. S
 liv hpa a      31.7mg * P<.02      10.4mg n.s.s.   1/50    1/50    3/49    1/52                                                   S
 ski sqp a      51.0mg Z P<.02      15.6mg n.s.s.   0/50    2/50    0/49    2/52                                                   S
 MXA adc a      102.mg * P<.02   e  28.8mg n.s.s.   0/50    0/50    2/49    1/52                                 col:adc; jej:adc.
 MXA adp a      264.mg * P<.02   e  60.1mg n.s.s.   0/50    0/50    0/49    2/52                                 col:adp; rec:adp.
 zym car a      297.mg * P<.02   c  89.8mg 454.gm   0/50    0/50    0/49    3/52
 TBA MXB a      1.36mg Z P<.0005    .943mg 2.10mg  44/50   48/50   45/49   51/52
 liv MXB a      23.0mg * P<.0005    9.02mg 116.mg   1/50    1/50    4/49    3/52                                  liv:hpa,hpb,hpc.

Mutagenicity in Salmonella: positive
SMILES Code for 1,2,3-Trichloropropane: ClC(CCl)CCl
InChI Code for 1,2,3-Trichloropropane: InChI=1/C3H5Cl3/c4-1-3(6)2-5/h3H,1-2H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for 1,2,3-Trichloropropane:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (support@leadscope.com).
Last updated: October 3, 2007

PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10